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Translational relevance  
Neoadjuvant chemotherapy offers estimation of treatment response as well as assessment of long 
term prognosis. In this study expression of 24 genes representing key biological processes was 
quantified in 126 residual tumours and 56 paired biopsies. Chemotherapy induced significant 
up- or downregulation of most genes, and in residual disease 14 genes representing proliferation, 
stromal activation, metabolism, apoptosis, stemcellness and Ras-ERK-activation predicted 
prognosis, suggesting a biological role in chemoresistant disease. In ER+/HER2- patients, 
ACACB, ERBB2, and PAWR, and in ER-/HER2- patients CD3D and PAWR, respectively, 
independently predicted prognosis. Multivariable gene models, providing prognostic information 
independently of ER-, PgR-, and HER2-status in all patients, and in ER+/HER2- patients, were 
also identified. Taken together, expression of the majority of the 24 genes was affected by 
chemotherapy, and most were also prognostic in residual disease. The multivariable gene models 
could, if validated, be used to identify patients needing additional post-neoadjuvant treatment to 
improve prognosis.  
 
Abstract  
Purpose: The primary aim was to derive evidence for or against the clinical importance of several 
biological processes in patients treated with neoadjuvant chemotherapy (NAC) by assessing 
expression of selected genes with prior implications in prognosis or treatment resistance. The 
secondary aim was to determine the prognostic impact in residual disease of the genes´ 
expression. 
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Patients and methods: Expression levels of 24 genes were quantified by NanoString nCounter 
on formalin-fixed paraffin-embedded residual tumours from 126 patients treated with NAC and 
56 paired presurgical biopsies. Paired t-test was used for testing changes in gene expression, and 
Cox regression and penalised elastic-net Cox Regression for estimating hazard ratios. 
Results: After NAC, 12 genes were significantly up- and 8 downregulated. Fourteen genes were 
significantly associated with time to recurrence in univariable analysis in residual disease. In a 
multivariable model ACACB, CD3D, MKI67, and TOP2A added prognostic value independent 
of clinical ER-, PgR-, and HER2-status. In ER+/HER2- patients ACACB, PAWR, and ERBB2 
predicted outcome, whereas CD3D and PAWR were prognostic in ER-/HER2- patients. By use 
of elastic-net analysis, a 6-gene signature (ACACB, CD3D, DECORIN, ESR1, MKI67, PLAU) 
was identified adding prognostic value independent of ER, PgR, and HER2. 
Conclusions: Most of the tested genes were significantly enriched or depleted in response to 
NAC. Expression levels of genes representing proliferation, stromal activation, metabolism, 
apoptosis, stemcellness, immunological response, and Ras-ERK-activation predicted outcome in 
residual disease. The multivariable gene models identified could, if validated, be used to identify 
patients needing additional post-neoadjuvant treatment to improve prognosis. 
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Background  
Tumour cells remaining after chemotherapy may be intrinsically resistant to chemotherapy and 
represent the disease which may later recur. There has, therefore, been an increasing interest in 
identifying genes/pathways enriched or depleted in residual tumours which may eventually be 
targetable and used for selection of patients to include in clinical trials on new drugs. Evidence for 
the clinical importance of these features may be obtained by establishing their long-term 
prognostic value, but this has been addressed infrequently, and many reports have focused on 
TNBC patients only, for whom no targetable treatment option is currently available.  
Neoadjuvant chemotherapy (NAC) offers the possibility of in vivo assessments of treatment 
response and increases the rates of breast conserving surgery. It has increased in breast cancer, as it 
has been proven equally effective as adjuvant treatment. Biological studies of residual disease after 
chemotherapy are much more straightforward in NAC than in metastatic disease because of ready 
access to biopsy tissue. 
With NAC approximately 10-15% of estrogen receptor (ER) positive and 30% of human 
epidermal growth factor receptor 2 (HER2)-negative and triple-negative breast cancers (TNBC) 
achieve a pathological complete response (pCR), which is now an FDA-approved surrogate end-
point for good long-term outcome and may be used for supporting accelerated approval of new 
drugs (1). For the majority of patients who do not achieve a pCR, the outcome is however more 
heterogeneous and difficult to predict (2). The residual cancer burden (RCB) is one validated 
long-term outcome predictive model (3). High residual Ki67 in the surgical sample, alone (4), or 
combined with RCB (Residual Proliferative Cancer Burden, RPCB) (5) have also been promising 
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in identifying patients with a poorer outcome who might be considered for inclusion in clinical 
studies with further treatment after surgery to improve outcome.  
The aims of the present study were to determine whether there was clinical evidence for the 
involvement of one or more from a panel of candidate genes in chemotherapy resistance. We 
determined this by studies of changes of gene expression on treatment, as well as the impact on 
long-term prognosis in a cohort including both ER+ and ER- patients treated with NAC. The 
genes were chosen from literature review on the basis of their being identified as (i) possible 
prognostic factors in residual disease at protein (4, 6-10) or mRNA level (11), (ii) as significantly 
up- or downregulated, but of unknown prognostic value in residual disease (12-20), (iii) as 
predictive of chemotherapy resistance (6, 11, 16, 19, 21-29), and/or (iv) identified as possible 
prognostic factors over several previous datasets (26, 30-41). In addition to the previously 
established prognostic factors ESR1 and ERBB2, the genes were also chosen to represent different 
pathways and biological processes of known implication in tumour progression or response to 
therapy, such as stemcellness (ALDH1A1, CD44, STAT3), proliferation (TOP2A, MKI67, 
AURKA), apoptosis (BCL2, BCL2L1, PAWR), immunological response (CD3D, CXCL13, 
STAT1), epithelial-to-mesenchymal transition (EMT) (SNAI1, SNAI2, SOX9, TWIST), stromal 
activation (DECORIN, SPARC, PLAU), energy metabolism (ACACB, LDHB), and ERK/Ras 
activation (DUSP 4). Changes in gene expression in response to NAC, as well as the long term 
prognostic value of gene expression in residual disease in all patients, and in subgroups based on 
ER- and HER2-status were chosen as endpoints. 
Material and Methods 
Patients 
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The 126 patients in the present study were derived from a previously described cohort from a 
study on the prognostic value of Ki67 in addition to RCB in residual disease after NAC (5). That 
study included 220 T1-4, N0/+, M0 patients who between 2001 and 2010 received NAC 
followed by surgery at the Royal Marsden Hospital. Patients were excluded from further analysis 
due to (i) pCR (n=49), (ii) insufficient tumour due to low cellularity (n=31), (iii) unavailability of 
tumour blocks (n=11), or (iv) insufficient RNA yield (n=3), see REMARK flow-chart, 
Supplementary Figure S1. Of the remaining 126 patients, 56 also had a paired pre-surgical biopsy 
available with sufficient tumour available for RNA extraction, taken at the time of diagnosis 
before start of chemotherapy. Details on treatments and baseline patient and tumour 
characteristics can be found in Table 1. The median follow-up for the end-point time to 
recurrence (TTR) for patients alive and free from relapse at the last review of the patients´ records 
was 4.1 years. 
Methods 
Pathological assessment of the biopsies and residual tumour tissue 
Pre- and post-treatment Ki67 was determined by the MIB-1 antibody (DAKO, K5001, 
Copenhagen, Denmark) on formalin-fixed paraffin embedded (FFPE) tissue by counting all, but 
no less than 200, invasive tumour cells in 5 high-power fields (x40 objective) representative of the 
tumour heterogeneity and recording the percentage of positively stained cells (42). CD3D in 
residual tumours tissue was determined by the use of the rabbit polyclonal CD3D antibody 
(Proteintech). CD3D-positive lymphocytes were assessed semi-quantitatively in relation to 
tumour size and scored as “low to moderate” and “high”. 
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Tissue macrodissection and mRNA extraction 
To identify samples and areas of interest for mRNA extraction, a 4m section from the residual 
surgical FFPE block was stained with H&E, and areas with ≥40% invasive tumour cells were 
outlined. One to six consecutive 8 m sections were cut on to slides, baked overnight at 37 
degrees and stained with a 1% solution of Nuclear Fast Red (NFR) (Sigma). The areas marked 
out on the H&E were identified on the NFR-stained sections, needle macrodissected, and 
collected into an RNAse free tube. Nucleic acid purification was performed using RecoverAll kit 
(Ambion) according to the manufacturer’s instructions, quantified by QubitRNA BR Assay kit 
(both Life Technologies) and stored at -20C. 
Gene expression profiles: NanoString nCounter analysis and data processing 
Expression of the 24 genes of interest (Supplementary Table S1) was assessed as part of a 
panel of 82 genes in which the other 58 were assessed for separate reasons and not considered 
further in this study other than for the purposes of analytical normalisation. Fifty to 100 
nanogram total RNA was analysed using a NanoString nCounter. Expression data was 
normalised with custom scripts in R. Background correction was done by subtracting the mean of 
the 8 negative control probes. Expression values were normalised with the three housekeeping 
genes that had the highest correlation amongst the housekeeping genes (ACTB, MPRL19, and 
TFRC). Expression values were log2 transformed and standardised within each sample. The 24 
genes in the present study were detected in >80% of the samples.  For residual samples, 
expression values were gene centred using a subpopulation of 86 samples with balanced ER+/ER- 
distribution.  
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Statistics 
The primary analysis was to evaluate changes in gene expression, and the secondary analysis was 
to investigate the prognostic value of gene expression in residual disease. The prognostic impact 
of gene expression in subgroups based on ER-and HER2-status, as well as multivariable models 
were secondary endpoints. Time to recurrence (TTR), with recurrences defined as local, regional, 
and/or distant, was the primary outcome endpoint. The Kaplan-Meier method was used to 
estimate TTR, and the log-rank test to compare survival in different strata. The univariable Cox 
regression analysis was used for estimation of hazard ratios (HR) of each gene. The null 
hypothesis of no prognostic effect by genes in ER-positive and ER-negative patients was tested 
using a Cox model with an interaction term between ER-status and the gene of interest. In 
univariable analyses, expression of the 24 genes was analysed as continuous variables as well as 
divided into tertiles. Analyses on the prognostic performance of the genes were performed in all 
patients, as well as in (i) subgroups based on ER and HER2-status (ER+/HER2- and ER-/HER2-
), (ii) in a fixed model incorporating clinical ER, PgR, HER2 adding one gene at a time, and 
lastly (iii) multivariable models including all 24 genes in all patients as well as in the ER+/HER2- 
subgroup. The Benjamini-Hochberg method was used for multiple hypothesis testing correction 
for all and subgroup univariable survival analysis. The threshold of q-values, that is the adjusted 
p-values from the false-discovery approach, was selected to be less than 1 false positive. For the 
multivariable survival analyses, the Penalised Elastic-Net Cox regression analysis was used to 
select genes with the best performance associated with survival outcome. Optimal alpha and 
lambda values were chosen following 10-fold cross validation. For the all patients analysis 
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selecting 6 genes: alpha=0.75, lambda=exp(−2.52777075921403); for the ER+/HER2- 
population selecting 4 genes: alpha=0.55; lambda=exp(−1.90897735668831). 
 Pearson´s and Spearman´s correlation tests were used to test the associations between clinical 
factors and/or genes, and paired t-test to assess changes in gene expression between presurgical 
biopsies and residual tumours. For analyses of gene expression patterns in residual disease, 
unsupervised two-way hierarchical clustering was performed by applying Pearson correlation and 
the Ward linkage method. All p-values correspond to two-sided tests and, unless otherwise stated, 
p<0.05 was considered significant. The statistical calculations were performed using the R 2.15 
version.  
 
 
Results 
Patient and tumour characteristics 
During follow-up, which due to non-proportional hazards was restricted to 5 years, 46 patients 
were diagnosed with local, regional, and/or distant recurrences and 32 patients died. At 5 years 
the overall survival was 75% (95% CI 67-83%). Detailed characteristics of the patients are 
presented in Table 1. Median age at diagnosis was 51 years, and 47% were node-positive at 
diagnosis.  Sixty-six% of cases were ER+, 52% PgR+, 12% HER2+, 62% ER+/HER2-, and 26% 
ER-/HER2-. The majority of HER2+ cases received trastuzumab (11/15) and 47% received this 
neoadjuvantly. Nearly all patients received anthracyline-containing chemotherapy (98%) and the 
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majority (64%) also received neoadjuvant taxanes. According to local practice at the time, before 
the routine use of neoadjvant taxanes, a proportion of patients treated with neoadjuvant 
anthracyclines went on to receive adjuvant taxane chemotherapy following surgery (14%). Forty-
eight% of the patients were treated with breast conserving surgery.  
 
Correlations  
Details of the gene set selected can be found in Supplementary Table S1. A correlation matrix of 
associations between the 24 genes and the IHC assessments of presurgical ER, HER2, and 
residual Ki67 can be found as Supplementary Figure S2. Residual IHC Ki67 was positively 
correlated with the expression of other proliferation genes and LDHB, and negatively correlated 
with IHC ER, ESR1, ACACB, ALDH1A1, BCL2, DECORIN, and TWIST, with the opposite 
correlation pattern for the same genes found for presurgical IHC ER. 
 
 
 
Changes in gene expression following neoadjuvant chemotherapy 
Of the 126 residual samples, there were 56 available presurgical biopsies, out of which 36 were 
ER+/HER2-, and 13 ER-/HER2-. In paired comparisons there was a significant dowregulation of 
all proliferation genes after chemotherapy (MKI67, TOP2A, AURKA), as well as BCL2L, PLAU, 
STAT1, and the stem cell markers CD44 and STAT3. The EMT genes SNAI1, SNAI2, SOX9, 
and TWIST, the apoptosis genes PAWR and BCL2, the Ras-ERK associated DUSP4, the 
metabolism-related genes ACACB and LDHB, ALDH1, and the stromal genes DECORIN and 
SPARC, were all significantly upregulated (Table 2). There were no significant changes in the 
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expression of ESR1, ERBB2, or the immune-related genes CD3D and CXCL13 (Table 2). 
Seventeen of these 20 genes were similarly significantly up- or downregulated in the ER+/HER2- 
patients (see Table 2). However, in the ER-/HER2-group, only SNAI2 and STAT1 changed 
significantly after chemotherapy (data not shown). 
 
Gene expression patterns in residual disease 
A heat map visualising the gene expression patterns in a dendrogram of the 24 genes in the 126 
residual tumours was determined after unsupervised clustering is shown in Figure 1. The first 
cluster consists of mainly ER-, HER2- tumours with high residual Ki67, and in this cluster of 41 
tumours the majority of relapses can be found (n=27). The cluster is characterised by 
overexpression of proliferation genes (MKI67, AURKA, TOP2A), and LDHB (indicating a 
glycolytic phenotype), the EMT genes SOX9 and SNAI1, and low expression of ESR1, ACACB 
(indicating an increase in fatty acid oxidation), BCL2, BCL2L1, the EMT genes TWIST and 
SNAI2, ALDH1A1, DUSP4 (indicating increased Ras-ERK activation), and DECORIN. In the 
other three clusters the majority of tumours are ER-positive, have lower residual Ki67 levels, and 
fewer relapses. This is reflected in an expression pattern reverse to the first cluster with lower 
expression levels of proliferation genes, and higher expression levels of ESR1 and genes strongly 
associated to ESR1. 
 
Relationship of gene expression in residual disease and prognosis: Univariable analyses  
In univariable analyses 14 genes representing proliferation (AURKA, MIK67, TOP2A), stromal 
activation (DECORIN, PLAU), metabolism (ACACB and LDHB), apoptosis (BCL2, BCL2L1), 
stemcellness (ALDH1A1), EMT (SNAI2, TWIST), Ras-ERK activation (DUSP4) and ESR1 were 
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significantly associated with TTR (Table 3). The strongest HRs were found for AURKA (HR 5.2, 
95%CI:1.9-14, p=0.001), LDHB (HR 4.1, 95%CI:2.0-8.1 p<0.0001), MIK67 (HR 3.9 95%CI: 
2.3-6.7, p<0.0001), DECORIN (HR 0.28, 95%CI: 0.17-0.48, p<0.0001), BCL2 (HR 0.29, 
95%CI: 0.17-0.49, p<0.0001), and ACACB (HR 0.32, 95%CI: 0.22-0.48, p<0.0001), (Table 3, 
Figures 2a-f).  
When dividing the gene expressions into tertiles, there were significant differences in 5-year TTR 
(log 1st tertile vs 2nd+3rd tertiles, log rank test) for ACACB (p<0.0001), ALDH1A1 (p=0.00018), 
BCL2 (p<0.0001), DECORIN (p<0.0001), ESR1 (p<0.0001), and MIK67 (highest 1st tertile vs 
2nd+3rd tertiles, p<0.0001), Figures 2a-f, but also AURKA, BCL2L1, CD44, DUSP4, ERBB2, 
LDHB, TOP2A, and TWIST (Supplementary Figures 3a-x). Notably there was a clear threshold 
effect for the expression levels of ESR1 and the proliferation genes, especially MIKI67. A similar 
pattern with threshold effects could be seen only for genes which were strongly correlated to 
either ESR1 or MIKI67 (ACACB, ALDA1, AURKA, TOP2A, BCL2, DECORIN, DUSP4, LDHB 
and TWIST), with no such effect found for genes with a weaker correlation to either MIKI67 or 
ESR1. 
Even though events were few in the subgroups, analyses of the prognostic value of the individual 
genes were performed to identify associations within subgroups defined by ER and HER2 status. 
Given that only 15 patients were HER2 positive, the exploratory analyses were restricted to the (i) 
ER+/HER2- (n=78, events=17) and (ii) ER-/HER2- subgroup (n=33, events=21). A strong 
prognostic effect was found for ACACB (HR 0.30, 95%CI:0.13-0.73, p=0.008), ERBB2 (HR 
0.12, 95%CI:0.02-0.76, p=0.025), and PAWR (HR 0.12, 95%CI: 0.02-0.61, p=0.011) in the 
ER+/HER2- patients, and PAWR (HR 7.3, 95%CI: 1.3-43, p=0.03) and CD3D (HR 0.41, 
95%CI: 0.19-0.87, p=0.02) in the ER-/HER2- patients, (Table 3). A significant differential 
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prognostic effect was seen for PAWR in ER+/HER2- and ER-/HER2- disease (interaction term 
HR 0.018, 95%CI: 0.002-0.19, p<0.001).  
 
Relationship between gene expression in residual disease and prognosis: Multivariable 
analyses 
Firstly a fixed multivariable model incorporating clinical factors of previously known prognostic 
value (ER, PgR, and HER2) was adjusted for one gene at a time for the 118 patients who had 
data available for all three clinical factors. In this model, MIK67 (HR 3.4, 95%CI:1.6-7.3, 
p=0.002), ACACB (HR 0.37, 95%CI:0.20-0.70 p=0.002), TOP2A (HR 2.2, 95%CI:1.2-4.2 
p=0.018) and CD3D (HR 0.56, 95%CI:0.31-0.92 p=0.024) added independent prognostic 
value, (Table 4). As an exploratory analysis, residual IHC Ki67 was added to form an IHC4 
model, and the findings were similar, with added prognostic information found for ACACB but 
also a retained prognostic value of MIK67 (Supplementary Table S2). 
For identifying genes in residual disease predictive of long term prognosis in multivariable models 
in (i) all patients (n=126), as well as in the largest subgroup, (ii) the ER+/HER2- patients (n=78), 
the elastic net Cox regression was used. In all patients, six genes with a non-zero regression 
coefficient were selected: ACAB, CD3D, DECORIN, ESR1, MIK67, and PLAU, predictive of 
outcome with a c-index of 0.79 in a multivariable Cox Proportional Hazards (CoxPH) model. 
The 6-gene model added prognostic value independent of the clinical base-line factors ER, PgR, 
and HER2 (p=0.0067), whereas ER, PgR, and HER2 did not add significant prognostic value in 
a Cox regression model that included the 6-gene model (c-index estimation 0.79). In the 
ER+/HER2- patients, 4 genes with a non-zero regression coefficient were selected; ACACB, 
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ERBB2, MIK67, and PAWR predictive of TTR with a c-index of 0.71 in a multivariable Cox 
regression model (data not shown).  
A statistically significant association was found between protein and mRNA expression of CD3D 
in the ER-/HER2- subset (n=32, p=0.008) supporting the possibility of a functional association, 
Supplementary Figure S4. 
Discussion 
The characteristics of the tumour cells surviving NAC are of major interest as they enable the 
study of changes in biological processes in response to chemotherapy and chemotherapy 
resistance, may represent the features of disease which may later recur, and are likely to provide 
information relevant to the long-term prognosis of patients with residual disease. Today as 
increasing numbers of patients are offered NAC, new prognosticators correctly identifying 
patients with an inferior prognosis in need of additional therapy after NAC is much needed. In 
this study we therefore sought to examine genes in residual disease and paired biopsies, 
representing different biological pathways with previously published implications for breast 
cancer prognosis or resistance to chemotherapy. Their relationship with long-term prognosis was 
examined to provide further support for their clinical relevance and to assess their potential for 
incorporation as a predictor of risk of recurrence. The prognostic value in subgroups based on 
ER- and HER2-status and multivariable models were considered secondary endpoints.  
Neoadjuvant chemotherapy affected the majority of the selected genes, with significant up- or 
downregulation of the expression levels of 12 and 8 genes, respectively. Only ESR1 and ERBB2, 
which are the major determinants of intrinsic subgroups, and CD3D, and CXCL13 remained 
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unchanged. As expected, the proliferation genes were all downregulated, consistent with 
proliferating tumour cells being more responsive to chemotherapy. However, tumours with high 
residual proliferation rates had a significantly worse long-term prognosis, with AURKA, TOP2A, 
and MKI67 all conferring prognostic information, validating previous results of the strong 
negative impact of high residual Ki67 alone (4) or as part of the RCB (5). Notably, there was an 
apparent threshold effect for MIKI67, with a probability of remaining relapse-free at 5-years of 
37%, compared with 84% for the highest and lowest tertiles, respectively. MKI67 and TOP2A 
also added prognostic value independent of clinical ER, PgR, and HER2-status in multivariable 
models predictive of long-term outcome in all patients, as well as in ER+/HER2- patients. 
Interestingly, IHC Ki67 and MIK67 were strongly correlated, but in an exploratory fixed model 
incorporating clinical ER, PgR, HER2, and IHC Ki67, MKI67 still added independent 
prognostic value to this model. Thus, while highly proliferative cells and tumours are more 
sensitive to chemotherapy, the persistence of highly proliferative cells in the face of chemotherapy 
is associated with very poor outcome. 
The stroma-associated genes DECORIN and SPARC were significantly upregulated after NAC, 
and high residual DECORIN was a strong predictor of improved outcome. The positive 
prognostic value of DECORIN found here in residual disease, as well as previously in primary 
ER-disease (30), could be explained by in vitro studies in which the proteoglycan decorin acts as a 
potent inhibitor of proliferation by interacting with transforming growth factor-β, epidermal 
growth factor receptor, insulin-like growth factor receptor, and low density lipoprotein receptor-
related protein (43). Moreover, DECORIN was chosen to represent an activated stroma in the 
Farmer metagene, with high levels predictive of resistance to chemotherapy in ER- disease (23). 
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High levels of PLAU and the corresponding protein u-PA, needed for breakdown of the 
extracellular matrix, have been associated with prediction of benefit of adjuvant chemotherapy 
and worse outcome (23, 44), and in the present data set a similar trend with a better outcome for 
low levels of PLAU was found. None of the stromal genes retained independent prognostic value 
in the multivariable models, which may be due to the strong correlation found with ER-status. 
Genes associated with reprogramming of energy metabolism, one of the hallmarks of cancer, were 
represented by LDBH and ACACB; both were upregulated after NAC and significantly associated 
with survival. High residual levels of LDHB, expressed in the microenvironment and suggestive of 
a glycolytic phenotype which bypasses oxidative phosphorylation, was associated with a poor 
outcome (6). This supports previous data in which high levels has been associated with a better 
response to NAC and impaired survival in residual TNBC (6). The Acetyl-CoA carboxylases 
(ACC) A and B, convert acetyl-CoA to malonyl-CoA, a rate limiting step in fatty acid synthesis.  
Where ACACA, localised in the cytosol, is mostly involved in fatty acid synthesis, high levels of 
ACACB, localised in the mitochondria, also regulate and inhibit fatty acid oxidation (45), which 
would account for the favourable outcome of patients with high levels of ACACB found in the 
present study, where inhibition of fatty acid oxidation impairs the energy requirements of the 
tumour cells. ACACB was, as in previous findings (14), enriched in residual disease irrespective of 
ER status. Even though there was a strong positive correlation between ACACB and ER-status, 
with the exception of ER-/HER2- patients, ACACB added independent prognostic value in all 
multivariable models also including ER or ESR1 status.  
Of the three apoptosis related genes chosen, high expression levels of BCL2, and to a lesser extent 
BCL2L1, was significantly associated with a better long-term outcome, as in earlier publications 
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both in primary tumours (34) and residual tumours after NAC (8). There was a significant 
upregulation of BCL2 and downregulation of BCL2L1 following neoadjuvant chemotherapy. 
Even though Bcl2 is mainly antiapoptotic, it is through the antiproliferative  (46) and 
proapaptotic  functions especially evident at higher expression levels which Bcl2 also exhibits 
(47), the positive prognostic value may emanate. Previous studies on the pro-apoptotic gene 
PAWR have found a negative prognostic value of low mRNA levels of PAWR in primary 
tumours, downregulation following NAC, but an unknown prognostic impact in residual disease 
(16). In the present study PAWR was upregulated in response to chemotherapy, but no 
significant univariable prognostic value could be found in all patients. However, there was a 
significant difference in the prognostic impact of PAWR in subgroups based on ER-status, where 
low levels of the pro-apoptotic gene PAWR in residual disease was significantly predictive of an 
improved outcome in the ER-/HER2- cohort only, with the reverse results found in ER+/HER2- 
tumours. This difference in prognostic impact based on ER-status also corresponded to a 
significant term of interaction. 
TWIST, SNAI1, SNAI2, and SOX9, the four EMT genes, are thought to facilitate EMT mainly 
by repressing e-cadherin expression needed for cells to maintain cell-to-cell adhesion, and high 
protein levels have generally been associated with an impaired prognosis in primary disease (40, 
41). In the present study the expression levels of all EMT genes were significantly upregulated 
after NAC in line with previous studies (14), however the prognostic value of high residual 
expression of the genes differed. Unexpectedly, high residual TWIST and SNAI2  was 
significantly associated with an improved outcome, whereas patients with low SNAI1 and SOX 9 
expression levels instead showed a non-significant trend towards improved survival (10, 15, 40). 
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Previous studies have only addressed the prognostic value of TWIST and SNAI2 in primary 
tumours, and there may be differences in profiling primary versus residual disease. An 
independent validation would however be needed to further elucidate the prognostic impact of 
TWIST and SNAI2 after NAC before definite conclusions can be drawn.  
In the present data set, of the stem cell markers CD44, STAT3, and ALDH1A1, generally 
associated with self-renewal and resistance to chemotherapy when expressed by epithelial cells in 
primary tumours, only high ALDH1A1, which was also significantly upregulated in response to 
neoadjuvant chemotherapy, conveyed independent prognostic value, and contrary to the 
expected, with high residual levels indicating an improved outcome. This may however be 
consistent with findings in another study on residual tumours, where no prognostic significance 
or increase in expression of epithelial ALDH1 was found after NAC, however, high residual 
stromal expression of ALDH1 was associated with an improved outcome (9). Moreover - even 
though ALDH1 is expressed at higher levels in chemotherapy resistant cancer stem cells (48), it 
also involved in the synthesis of retinoic acid, which has an antiproliferative effect by facilitating 
the action of other breast cancer cell growth inhibitors (49).  
An increase in immunological response, represented by CD3D, CXCL13, and STAT1 has been 
associated with improved survival in several publications (50). In this data set, CD3D, as part of 
immunological signatures proven predictive of NAC response (19) and prognosis (51), was the 
only immunological marker that displayed prognostic value in ER-/HER2- patients, in the 
clinical multivariable model adjusting for clinical ER, PgR, and HER2, and as part of the 6 gene 
predictive multivariable model. This is consistent with findings in a recent publication in which 
high levels of tumour-infiltrating lymphocytes, which are significantly associated with CD3D 
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expression (19), in residual disease were associated with in improved outcome in TNBC (50). We 
also found a significant statistical association between IHC CD3D and mRNA expression levels, 
supporting the possibility of a functional association. However, together with ESR1, ERBB2, 
neoadjuvant chemotherapy did not induce a significant change in either CXCL13 or CD3D 
expression.  
Lastly, the MAPK phosphatase DUSP4, a negative regulator of the Ras-ERK pathway  was 
significantly enriched in response to chemotherapy, with low levels of DUSP4 in residual disease 
associated with an impaired prognosis, in agreement with earlier studies on TNBC (11). Even so, 
there was no independent prognostic value of DUSP4 in any of the subgroups or in multivariable 
analyses. We chose not to conduct analyses of the MAPK pathway by measuring phosphorylated 
proteins since we have reported the catastrophic loss of immunohistochemical staining of p-AKT 
and p-ERK1/2 in routinely fixed breast cancer excisions (52). Pre-analytical variables may also 
affect transcript analyses but the inclusion of housekeeper genes helps cater for artefacts. Other 
studies have found DUSP4 mRNA expression inversely correlated with a gene-expression based 
Ras-ERK-pathway score in 230 primary breast cancers (11), and in 633 breast tumours from 
TCGA we observed an inverse correlation with BRAF and DUSP4 mRNA expression 
(Supplementary Table S3) (53). Taken together, although not directly linking DUPS4 expression 
to the phosphoprotein levels, this may provide evidence of the link between DUSP4 and Ras-
ERK-pathway activation.  
By studying the clinically relevant subgroups ER+/HER2- and ER-/HER2-, the dependence on 
ER (and HER2) signalling was assessed. Taken together, the majority of genes were dependent on 
the main prognostic drivers in breast cancer, and lost their prognostic impact in the subgroups. 
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However, as events are few, the results should be interpreted with caution. Apoptosis (PAWR), 
fatty acid synthesis (ACACB), and ERBB2 did however further identify patients with an inferior 
outcome in ER+/HER2- disease, and immune response (CD3D) and again PAWR emerged as 
prognostic biomarkers in ER-/HER2- patients. Notably HER2 expression was significantly 
associated with risk of relapse even in the HER2- cohort, with low rather than high expression 
associated with greater risk, consistent with our previous reports on the ABC and ATAC adjutant 
trials (54, 55). This may be partly due to a direct relationship between ER and HER2 expression 
in the HER2- group (with higher ER expression being linked to better prognosis) or to loss of 
that locus on chromosome 17 in genetically unstable, poorer prognosis tumors. Similarly, in a 
fixed multivariable IHC3 model including ER, PgR, and HER2, ACACB, CD3D, MKI67, and 
TOP2A provided independent prognostic value. Lastly, a penalised Elastic net Cox regression 
analysis in all patients identified six genes including ACACB, CD3D, DECORIN, ESR1, MKI67, 
and PLAU, which added significant prognostic value independent of clinical ER, PgR, and 
HER2. Conversely, clinical ER, PgR and HER2 did not provide additional prognostic value 
when the 6-gene model was included in the Cox model. In ER+/HER2- patient, a 4 gene model 
(ACACB, ERBB2, MKI67, and PAWR) was equally predictive of time to relapse. An external 
validation study would be required to further determine the clinical validity of the gene models 
identified from this study. However, in this study, we took a stringent approach to reduce the 
likelihood of false discovery: we applied a false discovery rate control approach to correct for 
multiple comparisons, and we set a threshold to control the expected proportion of falsely 
rejected null hypothesis to be less than 1% for the univariable analyses. For the multivariable 
analysis, the Elastic-net penalties regularisation method was used for gene selection, a useful 
approach when dealing with highly correlated covariates. 
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In conclusion, by profiling presurgical biopsies and residual disease in patients who have not 
achieved a pCR after NAC, the present study identified 14 genes representing ER-signalling 
(ESR1), proliferation (AURKA, MIK67, TOP2A), stem-cellness (ALDH1A1), EMT (TWIST, 
SNAI2), apoptosis (BCL2, BCL2L1, PAWR), changes in energy metabolism (LDHB, ACACB), 
stromal processes (DECORIN, PLAU), immunological response (CD3D), and Ras-ERK 
activation (DUSP4) which were all associated with an inferior prognosis. To determine their 
relative importance in individual patients and provide evidence for the targeting of these processes 
in chemo-resistant disease would need larger numbers of patients. The multivariable gene models 
identified in all patients as well as in the largest subgroup, the ER+/HER2- patients, could if they 
are validated be used to identify patients who could be offered further treatment or inclusion in 
studies on new drugs to improve their prognosis.  
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Table and Figure legends. 
 
Table 1: Patient characteristics of 126 patients with residual disease after neoadjuvant chemotherapy 
 
Table 2: Fold-changes in gene expression for all patients with available presurgical biopsies (n=56), but also 
including p-values for ER+/HER2- patients (n=36) 
 
Table 3: Univariable analyses of the prognostic value of the 24 genes with the end-point time to 
recurrence in all patients, the ER+HER2-, and the ER-/HER2- patients. 
 
Table 4: Multivariable fixed model consisting of clinical ER,PgR, and HER2, adjusted for one gene at 
a time with the end-point time to recurrence 
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Figure 1: Heat map of gene expression of 126 residual tumours analysed by unsupervised 
hierarchical clustering. Each column represents one tumour and each row a gene with red 
indicating upregulation, and green downregulation. Below the cluster dendrogram relapses, ER-, 
HER2-status, and residual Ki67 are indicated. The cluster dendrogram colourings have been 
made only for visualisation purposes using arbitrary cut-offs. 
Figures 2a-f: Kaplan-Meier curves with genes divided into tertiles for the 6 genes with the 
strongest hazard ratios with the end-point TTR for (a) ACACB (b) ALDHA1 (c) BCL2 (d) 
DECORIN (e) ESR1, and (f) MIK67 
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Table 1: Patient characteristics of 126 patients with residual disease after neoadjuvant chemotherapy 
 
Age, years 
    Median 
    Range 
Range (q1-q3) 
51 
26-75 
44-57 
Menopausal status, n  
              Pre 
              Post 
              Unknown/not applicable  
57 
46 
23 
T stage, n  
               T0 
               T1 
               T2 
               T3 
               T4 
               Unknown 
0 
4 
66 
36 
20 
0 
N stage, n  
               N0 
               N1 
               N2 
               N3 
               Unknown 
67 
55 
1  
3 
0 
AJCC Stage, n  
               1a 
               1b 
               2a 
               2b 
               3a 
               3b 
               3c 
0 
0 
46 
38 
19 
19 
4 
ER status, n  
               Negative 
               Positive 
               Unknown 
43 
83 
0 
   
2 
 
PgR status, n  
               Negative 
               Positive 
               Unknown 
53 
65 
8 
HER2 status, n (%) 
               Negative 
               Positive 
               Unknown 
111 
15 
0 
Grade, n (%) 
               I 
               II 
               III 
               Unknown 
4 
61 
57 
4 
Histology, n (%) 
               IDC 
               ILC 
               Mixed 
               Other    
111 
8 
7 
0 
Surgery, n (%) 
             Breast conservation 
             Mastectomy 
61 
65 
Neoadjuvant therapy, n (%) 
              Anthracycline 
              Taxane 
              Trastuzumab 
124 (98) 
81(64) 
7 (47) 
Adjuvant taxane, n (%) 20 (16)
Adjuvant endocrine therapy, n (%) 41 (33)
Adjuvant trastuzumab, n (%) 11(73)
Local, regional and/or distant metastases (≤ 5 years), n 46
Overall survival at 5 years, % 
       95% CI 
75%
67-83 
 
*for ER, PgR, and HER2- status pre-chemotherapy assessments on biopsies were used, if not available post-chemotherapy assessments were used. 
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Table 2: Fold-changes in gene expression for all patients with available presurgical biopsies (n=56), but also including p-values for ER+/HER2- patients (n=36) 
 
 All patients (n=56) ER+/HER2- patients (n=36)
Gene 
fold 
change 
samples 
upregulated 
samples 
downregulated 
p-value of change 
in expression 
p-value of change in 
expression 
ACACB 1.18 39 17 0.002 0.0002 
ALDH1A1 1.45 49 7 <0.0001 <0.0001 
AURKA 0.94 18 38 0.01 0.005 
BCL2 1.07 37 19 0.03 0.08 
BCL2L1 0.97 14 42 0.01 0.2 
CD3D 1.08 28 28 0.2 0.6 
CD44 0.92 16 40 0.002 <0.0001 
CXCL13 0.85 25 31 0.1 0.2 
DECORIN 1.22 45 11 <0.0001 <0.0001 
DUSP4 1.14 40 16 0.01 0.01 
ERBB2 0.94 20 36 0.07 0.2 
ESR1 0.97 23 33 0.5 0.3 
LDHB 1.07 37 19 0.004 <0.0001 
MKI67 0.68 10 46 <0.0001 <0.0001 
PAWR 1.05 38 18 0.01 0.03 
PLAU 0.86 15 41 0.001 0.0001 
SNAI1 1.08 34 22 0.03 0.01 
SNAI2 1.20 45 11 <0.0001 0.0003 
SOX9 1.11 40 16 0.0006 0.007 
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SPARC 1.11 38 18 0.008 0.1 
STAT1 0.84 8 48 <0.0001 <0.0001 
STAT3 0.95 20 36 0.002 0.0003 
TOP2A 0.70 13 43 <0.0001 <0.0001 
TWIST1 1.40 47 9 <0.0001 <0.0001 
*Fold change = mean of (post/pre) for 56 samples 
Table 3: Univariable analyses of the prognostic value of the 24 genes with the end-point time to recurrence in all patients, the ER+HER2-, and the ER-/HER2- 
patients.  
 All patients (n=126) ER+/HER2- (n=78) ER-/HER2- (n=33)
Events, n 46 17 21
Gene HR 95% CI P-value *q-value HR 95% CI P-value *q-value HR 95% CI P-value *q-value 
ACACB 0.32* 0.22-0.48 <0.0001 <0.0001 0.30* 0.13-0.73 0.0080 0.14 0.72 0.28-1.8 0.48 0.87
ALDH1A1 0.48* 0.35-0.65 <0.0001 <0.0001 0.72 0.23-2.2 0.57 0.95 0.74 0.46-1.2 0.23 0.80
AURKA 5.2* 1.9-14 <0.001 0.0028 1.43 0.17-12 0.74 0.96 4.36 0.77-25 0.097 0.54
BCL2 0.29* 0.17-0.49 <0.0001 <0.0001 0.45 0.14-1-5 0.19 0.78 0.75 0.30-1.9 0.55 0.87
BCL2L1 0.23* 0.07-0.77 0.017 0.034 0.65 0.05-8.0 0.74 0.96 2.03 0.33-12 0.44 0.87
CD3D 0.60 0.34-1.1 0.080 0.13 0.86 0.32-2.3 0.76 0.96 0.41* 0.19-0.87 0.020 0.33
CD44 2.4 0.75-7.8 0.14 0.19 0.29 0.03-2.3 0.25 0.86 2.27 0.40-13 0.35 0.87
CXCL13 1.2 0.86-1.5 0.34 0.38 1.03 0.66-1.6 0.91 0.96 1.11 0.63-1.9 0.73 0.87
DECORIN 0.28* 0.17-0.46 <0.0001 <0.0001 1.50 0.27-8.4 0.64 0.96 0.49 0.23-1.1 0.065 0.52
DUSP4 0.55* 0.36-0.83 0.005 0.010 0.72 0.30-1.7 0.47 0.95 1.18 0.47-3.0 0.73 0.87
ERBB2 0.92 0.49-1.7 0.79 0.79 0.12* 0.02-0.76 0.025 0.20 1.65 0.32-8.4 0.55 0.87
ESR1 0.52* 0.41-0.67 <0.0001 <0.0001 0.79 0.34-1.8 0.57 0.95 0.74 0.35-1.5 0.41 0.87
LDHB 4.1* 2.0-8.1 <0.0001 <0.001 3.68 0.59-23 0.16 0.78 0.80 0.25-2.5 0.70 0.87
MKI67 3.9* 2.3-6.7 <0.0001 <0.0001 2.70 1.0-7.0 0.041 0.24 1.95 0.55-6.9 0.30 0.87
PAWR 0.37 0.12-1.2 0.099 0.14 0.12* 0.02-0.61 0.011 0.14 7.31* 1.3-43 0.027 0.33
PLAU 2.5* 1.1-5.4 0.026 0.048 2.07 0.49-8.8 0.32 0.86 1.24 0.48-3.1 0.65 0.87
SNAI1 1.4 0.56-3.5 0.48 0.50 1.60 0.38-6.8 0.53 0.95 0.78 0.16-4.0 0.76 0.87
SNAI2 0.45* 0.22-0.92 0.028 0.048 0.93 0.24-3.6 0.92 0.96 1.25 0.43-3.7 0.68 0.87
SOX9 1.5 0.68-3.2 0.32 0.38 1.02 0.26-4.0 0.97 0.97 0.55 0.21-1.4 0.21 0,80
SPARC 0.53 0.25-1.1 0.091 0.14 2.16 0.50-9.3 0.30 0.86 0.89 0.31-2.6 0.83 0.91
STAT1 1.5 0.64-3.5 0.35 0.38 1.42 0.39-5.2 0.59 0.95 1.45 0.33-6.3 0.62 0.87
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* Genes identified by the The Benjamini and Hochberg method for multiple comparison correction, for all patients and subgroups, The threshold of q-values, that is the adjusted p-
values from the false-discovery approach, was selected to be less than 1 false positive. 
 
 
 
Table 4: Multivariable fixed model consisting of clinical ER,PgR, and HER2, adjusted for one gene at a time with the end-point time to recurrence 
  
STAT3 0.37 0.06-2.4 0.29 0.37 1.55 0.05-50 0.81 0.96 1.17 0.15-9.3 0.88 0.92
TOP2A 2.5* 1.5-4.2 <0.001 0.002 1.35 0.61-3.0 0.46 0.95 2.68 0.79-9,1 0.11 0.54
TWIST1 0.41* 0.23-0.73 0.0026 0.0063 1.10 0.31-3.9 0.88 0.96 1.00 0.35-2.8 1.00 1.00
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 All patients, univariable analysis (n=118) Fixed model of ER, PgR, and HER2 adjusted for 1 gene at a time (n=118)
Events, n 43 43 
Clinical factor/ gene HR 95% CI P-value HR 95% CI P-value *q-value 
IHC ER 0.21 0.11-0.39 <0.0001 NA NA NA NA 
IHC PgR 0.31 0.16-0.57 0.00023 NA NA NA NA 
IHC HER2 1.58 0.7-3.6 0.27 NA NA NA NA 
ACACB 0.3 0.2-0.45 <0.0001 0.37* 0.20-0.70 0.0022 0.027 
ALDH1A1 0.47 0.34-0.64 <0.0001 0.69 0.45-1.06 0.087 0.27 
AURKA 4.9 1.8-13 0.0020 2.8 0.83-9.6 0.098 0.27 
BCL2 0.27 0.15-0-47 <0.0001 0.50 0.24-1.1 0.074 0.27 
BCL2L1 0.2 0.06-0.69 0.011 0.27 0.29-5.0 0.80 0.96 
CD3D 0.59 0.33-1.0 0.065 0.56* 0.31-0.92 0.024 0.14 
CD44 2.5 0.76-8.4 0.13 2.2 0.38-64.9 0.64 0.91 
CXCL13 1.1 0.81-1.5 0.56 0.95 0.68-1.3 0.74 0.94 
DECORIN 0.28 0.17-0.47 <0.0001 0.50 0.25-0.98 0.043 0.21 
DUSP4 0.57 0.37-0.69 0.010 1.2 0.68-2.1 0.53 0.86 
ERBB2 0.89 0.47-1.7 0.73 1.00 0.38-2.6 0.99 1.0 
ESR1 0.52 0.4-0.67 <0.0001 0.67 0.41-1.1 0.10 0.27 
LDHB 4.14 2.0-8.4 <0.0001 1.3 0.49-3.6 0.59 0.88 
MKI67 5.04 2.7-9.3 <0.0001 3.4* 1.6-7.3 0.0021 0.027 
PAWR 0.53 0.15-1.9 0.34 2.0 0.49-8.6 0.33 0.66 
PLAU 2.6 1.2-5.9 0.017 1.7 0.80-3.6 0.17 0.41 
SNAI1 1.5 0.57-3.9 0.41 0.95 0.34-2.7 0.92 0.96 
SNAI2 0.45 0.22-0.92 0.029 0.95 0.42-2.2 0.91 0.96 
SOX9 1.5 0.68-3.3 0.32 0.69 0.62-1.3 0.22 0.48 
SPARC 0.54 0.25-1.2 0.12 1.2 0.51-2.7 0.71 0.94 
STAT1 1.5 0.65-3.6 0.32 1.4 0.55-3.7 0.45 0.82 
STAT3 0.41 0.06-2.7 0.35 1.1 0.21-6.1 0.87 0.95 
TOP2A 3.1 1.7-5.6 0.00015 2.2* 1.2-4.2 0.018 0.14 
TWIST1 0.37 0.2-0.68 0.0013 0.75 0.34-1.7 0.48 0.82 
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* Genes identified by the The Benjamini and Hochberg method for multiple comparison correction, for all patients and subgroups, The threshold of q-values, that is the adjusted p-
values from the false-discovery approach, was selected to be less than 1 false positive. 
